Melanoma Risk and Survival among Organ Transplant Recipients

Journal of Investigative Dermatology

Volumn 135, Issue 11, 2015, Pages 2657-2665

  Robbins, Hilary A ^a,l   Clarke, Christina A ^b,c   Arron, Sarah T ^d   Tatalovich, Zaria ^a   Kahn, Amy R ^e   Hernandez, Brenda Y ^f   Paddock, Lisa ^g,h   Yanik, Elizabeth L ^a   Lynch, Charles F ⁱ   Kasiske, Bertram L ^j   Snyder, Jon ^k   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e New York State Cancer Registry   (United States)

^f UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^g New Jersey State Cancer Registry   (United States)

^h RUTGERS SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^k MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^l JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE;

ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CAUSE OF DEATH; COMPARATIVE STUDY; DEMOGRAPHY; FEMALE; GRAFT RECIPIENT; HUMAN; INVASIVE MELANOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; STANDARDIZED INCIDENCE RATIO; SURVIVAL; T CELL DEPLETION; TUMOR LOCALIZATION; ULTRAVIOLET RADIATION; ADULT; ADVERSE EFFECTS; AGE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ORGAN TRANSPLANTATION; PATHOLOGY; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; SEX DIFFERENCE; SKIN TUMOR; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TUMOR INVASION;

ADULT; AGE FACTORS; CASE-CONTROL STUDIES; CAUSE OF DEATH; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN TRANSPLANTATION; POISSON DISTRIBUTION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; SEX FACTORS; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TRANSPLANT RECIPIENTS;

EID: 84947025795     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.312     Document Type: Article

References (50)

1. Adami J, Frisch M, Yuen J et al. (1995) Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 310:1491-5
2. Azimi F, Scolyer RA, Rumcheva P et al. (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30:2678-83
3. Barker JN, MacDonald DM (1988) Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol 13:123-5
4. Brewer JD, Christenson LJ, Weaver AL et al. (2011) Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol 147:790-6
5. Brewer JD, Shanafelt TD, Otley CC et al. (2012) Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol 30:843-9
6. Chatrath H, Berman K, Vuppalanchi R et al. (2013) De novo malignancy post-liver transplantation: a single center, population controlled study. Clin Transplant 27:582-90
7. CivicSpace Labs (2004) CivicSpace U.S. ZIP Code Database. Available at http://www.boutell.com/zipcodes/; accessed on 30 March 2014
8. Clarke CA, Robbins HA, Tatalovich Z et al. (2015) Risk of merkel cell carcinoma after solid organ transplantation. J Natl Cancer Inst 107(2)
9. Cockburn M, Swetter SM, Peng D et al. (2008) Melanoma underreporting: why does it happen, how big is the problem, and how do we fix it? J Am Acad Dermatol 59:1081-5
10. Cormier JN, Xing Y, Ding M et al. (2006) Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 166:1907-14
11. Dahlke E, Murray CA, Kitchen J et al. (2014) Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transplant Res 3:10
12. Eide MJ, Weinstock MA (2005) Association of UV index, latitude, and melanoma incidence in nonwhite populations-US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol 141:477-81
13. Engels EA, Pfeiffer RM, Fraumeni JF Jr et al. (2011) Spectrum of cancer risk among US solid organ transplant recipients. JAMA 306:1891-901
14. Fong ZV, Tanabe KK (2014) Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol 170:20-30
15. Grob JJ, Bastuji-Garin S, Vaillant L et al. (1996) Excess of nevi related to immunodeficiency: a study in HIV-infected patients and renal transplant recipients. J Investig Dermatol Symp Proc 107:694-7
16. Grulich AE, van Leeuwen MT, Falster MO et al. (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59-67
17. Hamid O, Robert C, Daud A et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-44
18. Han W, Soltani K, Ming M et al. (2012) Deregulation of XPC and CypA by cyclosporin A: an immunosuppression-independent mechanism of skin carcinogenesis. Cancer Prev Res 5:1155-62
19. Hisada M, Biggar RJ, Greene MH et al. (2001) Solid tumors after chronic lymphocytic leukemia. Blood 98:1979-81
20. Hojo M, Morimoto T, Maluccio M et al. (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530-4
21. Hollenbeak CS, Todd MM, Billingsley EM et al. (2005) Increased incidence of melanoma in renal transplantation recipients. Cancer 104:1962-7
22. Holman CD, Armstrong BK, Heenan PJ (1986) Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst 76:403-14
23. Jensen P, Hansen S, Moller B et al. (1999) Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 40:177-86
24. Kasiske BL, Snyder JJ, Gilbertson DT et al. (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4:905-13
25. Kubica AW, Brewer JD (2012) Melanoma in immunosuppressed patients. Mayo Clin Proc 87:991-1003
26. Lennerz V, Fatho M, Gentilini C et al. (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102:16013-8
27. MacKie RM, Reid R, Junor B (2003) Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 348:567-8
28. Matin RN, Mesher D, Proby CM et al. (2008) Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases. Am J Transplant 8:1891-900
29. McGregor JM, Barker JN, MacDonald DM (1991) The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin Exp Dermatol 16:131-2
30. Nelemans PJ, Groenendal H, Kiemeney LA et al. (1993) Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sunsensitive individuals. Environ Health Perspect 101:252-5
31. O'Donovan P, Perrett CM, Zhang X et al. (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309:1871-4
32. Olsen CM, Carroll HJ, Whiteman DC (2010) Estimating the attributable fraction for cancer: a meta-analysis of nevi and melanoma. Cancer Prev Res 3: 233-45
33. Rhodes AR, Weinstock MA, Fitzpatrick TB et al. (1987) Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 258:3146-54
34. Rodrigues LK, Klencke BJ, Vin-Christian K et al. (2002) Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 138:765-70
35. Siegel R, Ma J, Zou Z et al. (2014) Cancer statistics, 2014. CA Cancer J Clin 64: 9-29
36. Smith CH, McGregor JM, Barker JN et al. (1993) Excess melanocytic nevi in children with renal allografts. J Am Acad Dermatol 28:51-5
37. Strauss DC, Thomas JM (2010) Transmission of donor melanoma by organ transplantation. Lancet Oncol 11:790-6
38. Tatalovich Z, Wilson JP, Cockburn M (2006a) A comparison of Thiessen polygon, kriging, and spline models of potential UV exposure. Cartogr Geogr Inf Sci 33:217-31
39. Tatalovich Z, Wilson JP, Mack T et al. (2006b) The objective assessment of lifetime cumulative ultraviolet exposure for determining melanoma risk. J Photochem Photobiol B 85:198-204
40. Taylor RC, Patel A, Panageas KS et al. (2007) Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25:869-75
41. Travis LB, Curtis RE, Hankey BF et al. (1992) Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 84:1422-7
42. Ulrich C, Jurgensen JS, Degen A et al. (2009) Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 161(Suppl 3): 78-84
43. Ulrich C, Kanitakis J, Stockfleth E et al. (2008) Skin cancer in organ transplant recipients-where do we stand today? Am J Transplant 8:2192-8
44. United States Department of Health and Human Services (2014) The Surgeon General's Call to Action to Prevent Skin Cancer. Washington, DC: U.S. Department of Health and Human Services, Office of the Surgeon General
45. Vajdic CM, Chong AH, Kelly PJ et al. (2014) Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study. Am J Transplant 14:1368-75
46. Vajdic CM, van Leeuwen MT, Webster AC et al. (2009) Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev 18:2297-303
47. van Houdt IS, Sluijter BJ, Moesbergen LM et al. (2008) Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. Int J Cancer 123:609-15
48. van Leeuwen MT, Webster AC, McCredie MR et al. (2010) Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ 340:c570
49. Welch HG, Woloshin S, Schwartz LM (2005) Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 331:481
50. Wolchok JD, Kluger H, Callahan MK et al. (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122-33